Skip to main content
PIRAMAL PHARMA LIMITED logo

PIRAMAL PHARMA LIMITED — Investor Relations & Filings

Ticker · PPLPHARMA ISIN · INE0DK501011 LEI · 3358006D6AL7PZ4U9T51 BSE.NS Manufacturing
Open in API
Filings indexed 369 across all filing types
Latest filing 2026-06-05 Share Issue/Capital Cha…
Country IN India
Listing BSE.NS PPLPHARMA

About PIRAMAL PHARMA LIMITED

https://www.piramalpharma.com/

Piramal Pharma Limited provides a broad range of products and services across the drug lifecycle through three main business segments: Piramal Pharma Solutions, Piramal Critical Care, and Consumer Healthcare. Piramal Pharma Solutions operates as an integrated Contract Development and Manufacturing Organization (CDMO), offering end-to-end services from drug discovery and development to commercial manufacturing of APIs and formulations. Piramal Critical Care focuses on complex hospital generics, holding a significant global market share in inhalation anesthetics, including Sevoflurane and Isoflurane, as well as injectable anesthesia and pain management therapies. The Consumer Healthcare division manages a diverse portfolio of over-the-counter brands such as Saridon, Lacto Calamine, and Tetmosol. The company leverages an extensive global manufacturing network to deliver specialized healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
ESOP/ESOS/ESPS
Share Issue/Capital Change Classification · 95% confidence The document is an official stock exchange disclosure under SEBI Listing Regulations disclosing the allotment of new equity shares under an ESOP scheme. It details the number of shares issued, change in paid-up capital, and related regulatory disclosures. This constitutes an announcement of a share issue/capital change rather than an annual or interim report, management discussion, or other filings.
2026-06-05 English
Please find enclosed intimation of allotment of ESOPs.
Share Issue/Capital Change Classification · 92% confidence The document is a stock exchange filing under SEBI Listing Regulations disclosing the allotment of 2,100,000 equity shares to the company’s ESOP Trust, and the consequent increase in paid-up share capital. This is an announcement of a new share issue/capital change, which falls squarely under the Share Issue/Capital Change category (Code: SHA).
2026-06-05 English
Action(s) taken or orders passed
Regulatory Filings Classification · 85% confidence The document is a formal disclosure letter under Regulation 30 of the SEBI Listing Regulations to BSE and NSE about the permanent revocation of closure directions by the Gujarat Pollution Control Board. It is a compliance/continuous disclosure announcement rather than a full report, earnings release, or ESG report. It therefore fits the Regulatory Filings (RNS) category as a general regulatory announcement.
2026-06-03 English
Permanent revocation of closure directions for Company''s Dahej Site
Regulatory Filings Classification · 88% confidence The document is a stock exchange disclosure under SEBI Listing Regulations about the permanent revocation of closure directions by a pollution control board. It is a regulatory compliance announcement sent to BSE/NSE, not a financial report, ESG report, legal proceedings update, or any other specific category. It falls into the general regulatory announcements/fallback category.
2026-06-03 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 88% confidence The document is a formal notice filed under SEBI Listing Obligations to inform the exchanges of upcoming analyst/institutional investor meetings. It does not present financial results, a presentation deck, or voting outcomes, nor is it an annual or interim report. It is a regulatory disclosure of schedule under Listing Regulations, fitting the general category of miscellaneous regulatory announcements. Thus, it should be classified as a Regulatory Filing (RNS).
2026-06-01 English
Intimation of Schedule of Analyst/ Institutional Investor Meetings under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
Regulatory Filings Classification · 85% confidence The document is a regulatory disclosure under SEBI LODR, notifying stock exchanges of upcoming analyst/institutional investor meetings. It does not contain financial statements or provide investor presentation materials; rather, it is a routine compliance announcement. This aligns with the 'Regulatory Filings' category as a general regulatory announcement.
2026-06-01 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.